Exploring the therapeutic potential of natural compounds modulating the endocannabinoid system in various diseases and disorders: review
Pharmacol Rep. 2023 Oct 31. doi: 10.1007/s43440-023-00544-7. Online ahead of print.ABSTRACTCannabinoid receptors, endogenous cannabinoids (endocannabinoids), and the enzymes involved in the biosynthesis and degradation of the endocannabinoids make up the endocannabinoid system (ECS). The components of the ECS are proven to modulate a vast bulk of various physiological and pathological processes due to their abundance throughout the human body. Such discoveries have attracted the researchers' attention and emerged as a potential therapeutical target for the treatment of various diseases. In the present article, we reviewed ...
Source: Pharmacological Reports - October 31, 2023 Category: Drugs & Pharmacology Authors: Gidion Wilson Lingling Yang Xiaojuan Su Shuqin Ding Liuyan Li Youyue Yang Xiaoying Wang Weibiao Wang Yuping Sa Yue Zhang Jianyu Chen Xueqin Ma Source Type: research
Introduction to the thematic collection "Psychedelic Medicine: Therapeutic Applications and Implications for Future Research"
Pharmacol Rep. 2023 Oct 31. doi: 10.1007/s43440-023-00549-2. Online ahead of print.NO ABSTRACTPMID:37904067 | DOI:10.1007/s43440-023-00549-2 (Source: Pharmacological Reports)
Source: Pharmacological Reports - October 31, 2023 Category: Drugs & Pharmacology Authors: Krystyna Go łembiowska Source Type: research
Exploring the therapeutic potential of natural compounds modulating the endocannabinoid system in various diseases and disorders: review
Pharmacol Rep. 2023 Oct 31. doi: 10.1007/s43440-023-00544-7. Online ahead of print.ABSTRACTCannabinoid receptors, endogenous cannabinoids (endocannabinoids), and the enzymes involved in the biosynthesis and degradation of the endocannabinoids make up the endocannabinoid system (ECS). The components of the ECS are proven to modulate a vast bulk of various physiological and pathological processes due to their abundance throughout the human body. Such discoveries have attracted the researchers' attention and emerged as a potential therapeutical target for the treatment of various diseases. In the present article, we reviewed ...
Source: Pharmacological Reports - October 31, 2023 Category: Drugs & Pharmacology Authors: Gidion Wilson Lingling Yang Xiaojuan Su Shuqin Ding Liuyan Li Youyue Yang Xiaoying Wang Weibiao Wang Yuping Sa Yue Zhang Jianyu Chen Xueqin Ma Source Type: research
Introduction to the thematic collection "Psychedelic Medicine: Therapeutic Applications and Implications for Future Research"
Pharmacol Rep. 2023 Oct 31. doi: 10.1007/s43440-023-00549-2. Online ahead of print.NO ABSTRACTPMID:37904067 | DOI:10.1007/s43440-023-00549-2 (Source: Pharmacological Reports)
Source: Pharmacological Reports - October 31, 2023 Category: Drugs & Pharmacology Authors: Krystyna Go łembiowska Source Type: research
Exploring the therapeutic potential of natural compounds modulating the endocannabinoid system in various diseases and disorders: review
Pharmacol Rep. 2023 Oct 31. doi: 10.1007/s43440-023-00544-7. Online ahead of print.ABSTRACTCannabinoid receptors, endogenous cannabinoids (endocannabinoids), and the enzymes involved in the biosynthesis and degradation of the endocannabinoids make up the endocannabinoid system (ECS). The components of the ECS are proven to modulate a vast bulk of various physiological and pathological processes due to their abundance throughout the human body. Such discoveries have attracted the researchers' attention and emerged as a potential therapeutical target for the treatment of various diseases. In the present article, we reviewed ...
Source: Pharmacological Reports - October 31, 2023 Category: Drugs & Pharmacology Authors: Gidion Wilson Lingling Yang Xiaojuan Su Shuqin Ding Liuyan Li Youyue Yang Xiaoying Wang Weibiao Wang Yuping Sa Yue Zhang Jianyu Chen Xueqin Ma Source Type: research
Introduction to the thematic collection "Psychedelic Medicine: Therapeutic Applications and Implications for Future Research"
Pharmacol Rep. 2023 Oct 31. doi: 10.1007/s43440-023-00549-2. Online ahead of print.NO ABSTRACTPMID:37904067 | DOI:10.1007/s43440-023-00549-2 (Source: Pharmacological Reports)
Source: Pharmacological Reports - October 31, 2023 Category: Drugs & Pharmacology Authors: Krystyna Go łembiowska Source Type: research
Psychedelics action and schizophrenia
Pharmacol Rep. 2023 Oct 30. doi: 10.1007/s43440-023-00546-5. Online ahead of print.ABSTRACTPsychedelics are compounds acting by serotonin 5-hydroxytryptamine (5-HT)2A receptor activation and induce several behavioral responses. They are of special interest because of their positive effects on neuropsychiatric disorders (depression and posttraumatic stress disorder). However, several findings revealed that some psychedelic actions are similar to symptoms observed in schizophrenia (psychosis, sensorimotor gating impairments, attention, and working memory deficits) which might limit their clinical applications. Psychedelics a...
Source: Pharmacological Reports - October 30, 2023 Category: Drugs & Pharmacology Authors: Marzena Ma ćkowiak Source Type: research
Preclinical models of treatment-resistant depression: challenges and perspectives
Pharmacol Rep. 2023 Oct 26. doi: 10.1007/s43440-023-00542-9. Online ahead of print.ABSTRACTTreatment-resistant depression (TRD) is a subgroup of major depressive disorder in which the use of classical antidepressant treatments fails to achieve satisfactory treatment results. Although there are various definitions and grading models for TRD, common criteria for assessing TRD have still not been established. However, a common feature of any TRD model is the lack of response to at least two attempts at antidepressant pharmacotherapy. The causes of TRD are not known; nevertheless, it is estimated that even 60% of TRD patients ...
Source: Pharmacological Reports - October 26, 2023 Category: Drugs & Pharmacology Authors: Magdalena Kolasa Agata Faron-G órecka Source Type: research
Preclinical models of treatment-resistant depression: challenges and perspectives
Pharmacol Rep. 2023 Oct 26. doi: 10.1007/s43440-023-00542-9. Online ahead of print.ABSTRACTTreatment-resistant depression (TRD) is a subgroup of major depressive disorder in which the use of classical antidepressant treatments fails to achieve satisfactory treatment results. Although there are various definitions and grading models for TRD, common criteria for assessing TRD have still not been established. However, a common feature of any TRD model is the lack of response to at least two attempts at antidepressant pharmacotherapy. The causes of TRD are not known; nevertheless, it is estimated that even 60% of TRD patients ...
Source: Pharmacological Reports - October 26, 2023 Category: Drugs & Pharmacology Authors: Magdalena Kolasa Agata Faron-G órecka Source Type: research
Preclinical models of treatment-resistant depression: challenges and perspectives
Pharmacol Rep. 2023 Oct 26. doi: 10.1007/s43440-023-00542-9. Online ahead of print.ABSTRACTTreatment-resistant depression (TRD) is a subgroup of major depressive disorder in which the use of classical antidepressant treatments fails to achieve satisfactory treatment results. Although there are various definitions and grading models for TRD, common criteria for assessing TRD have still not been established. However, a common feature of any TRD model is the lack of response to at least two attempts at antidepressant pharmacotherapy. The causes of TRD are not known; nevertheless, it is estimated that even 60% of TRD patients ...
Source: Pharmacological Reports - October 26, 2023 Category: Drugs & Pharmacology Authors: Magdalena Kolasa Agata Faron-G órecka Source Type: research
Preclinical models of treatment-resistant depression: challenges and perspectives
Pharmacol Rep. 2023 Oct 26. doi: 10.1007/s43440-023-00542-9. Online ahead of print.ABSTRACTTreatment-resistant depression (TRD) is a subgroup of major depressive disorder in which the use of classical antidepressant treatments fails to achieve satisfactory treatment results. Although there are various definitions and grading models for TRD, common criteria for assessing TRD have still not been established. However, a common feature of any TRD model is the lack of response to at least two attempts at antidepressant pharmacotherapy. The causes of TRD are not known; nevertheless, it is estimated that even 60% of TRD patients ...
Source: Pharmacological Reports - October 26, 2023 Category: Drugs & Pharmacology Authors: Magdalena Kolasa Agata Faron-G órecka Source Type: research
Cardiovascular safety of psychedelic medicine: current status and future directions
Pharmacol Rep. 2023 Oct 24. doi: 10.1007/s43440-023-00539-4. Online ahead of print.ABSTRACTPsychedelics are powerful psychoactive substances that alter perception and mood processes. Their effectiveness in the treatment of psychiatric diseases was known before their prohibition. An increasing number of recent studies, due to the indisputable resurgence of serotonergic hallucinogens, have shown their efficacy in alleviating depression, anxiety, substance abuse therapies, and existential distress treatment in patients facing life-threatening illness. Psychedelics are generally considered to be physiologically safe with low t...
Source: Pharmacological Reports - October 24, 2023 Category: Drugs & Pharmacology Authors: Agnieszka Ws ół Source Type: research
Olanzapine alters the expression of gasotransmitter-related enzymes: CBS and HO-2 in the rat hippocampus and striatum
CONCLUSIONS: Modulatory effect of olanzapine on cellular mechanisms of gasotransmitter synthesis may be an alternative way of their pharmacological action.PMID:37874531 | DOI:10.1007/s43440-023-00538-5 (Source: Pharmacological Reports)
Source: Pharmacological Reports - October 24, 2023 Category: Drugs & Pharmacology Authors: Artur Pa łasz Julia Kistowska Aleksandra Suszka- Świtek Marek Krzystanek Iwona B łaszczyk Itiana Castro Menezes Łukasz Filipczyk Katarzyna Bogus Source Type: research
Cardiovascular safety of psychedelic medicine: current status and future directions
Pharmacol Rep. 2023 Oct 24. doi: 10.1007/s43440-023-00539-4. Online ahead of print.ABSTRACTPsychedelics are powerful psychoactive substances that alter perception and mood processes. Their effectiveness in the treatment of psychiatric diseases was known before their prohibition. An increasing number of recent studies, due to the indisputable resurgence of serotonergic hallucinogens, have shown their efficacy in alleviating depression, anxiety, substance abuse therapies, and existential distress treatment in patients facing life-threatening illness. Psychedelics are generally considered to be physiologically safe with low t...
Source: Pharmacological Reports - October 24, 2023 Category: Drugs & Pharmacology Authors: Agnieszka Ws ół Source Type: research
Olanzapine alters the expression of gasotransmitter-related enzymes: CBS and HO-2 in the rat hippocampus and striatum
CONCLUSIONS: Modulatory effect of olanzapine on cellular mechanisms of gasotransmitter synthesis may be an alternative way of their pharmacological action.PMID:37874531 | DOI:10.1007/s43440-023-00538-5 (Source: Pharmacological Reports)
Source: Pharmacological Reports - October 24, 2023 Category: Drugs & Pharmacology Authors: Artur Pa łasz Julia Kistowska Aleksandra Suszka- Świtek Marek Krzystanek Iwona B łaszczyk Itiana Castro Menezes Łukasz Filipczyk Katarzyna Bogus Source Type: research
